Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 22;11(10):2922.
doi: 10.3390/jcm11102922.

Methylphenidate Use for Emotional Dysregulation in Children and Adolescents with ADHD and ADHD and ASD: A Naturalistic Study

Patrizia Ventura  1 , Concetta de Giambattista  1 , Paolo Trerotoli  2 , Maddalena Cavone  1 , Alessandra Di Gioia  1 , Lucia Margari  1
Affiliations

Methylphenidate Use for Emotional Dysregulation in Children and Adolescents with ADHD and ADHD and ASD: A Naturalistic Study

Patrizia Ventura et al. J Clin Med. .

Abstract

Emotional dysregulation (ED) is common in attention-deficit/hyperactivity disorder (ADHD). Nonetheless, research on ADHD in children with autism spectrum disorder (ASD) and ADHD is still ongoing. Several studies suggest that methylphenidate (MPH) may be effective for ED in ADHD, while there is not enough evidence about its use in ASD with comorbid ADHD. This naturalistic study aims to investigate the effectiveness of immediate- and extended-release MPH in the treatment of ED in 70 children and adolescents (6-18 years), with a diagnosis of ADHD (n = 41) and of ASD with comorbid ADHD (n = 29), using the Child Behavior Checklist-Attention/Aggressive/Anxious (CBCL-AAA). Their parents completed the CBCL twice-first during the summer medication-free period, that is, at least one month after drug interruption; and again after three months of treatment restart. Results demonstrate that MPH is associated with a statistically significant reduction in ED in ADHD and ASD, without substantial adverse events, supporting the use of psychostimulants for the treatment of ED in these neurodevelopmental disorders.

Keywords: ADHD; ASD; ED; MPH; attention-deficit/hyperactivity disorder; autism spectrum disorder; emotional dysregulation; methylphenidate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Van Stralen J. Emotional dysregulation in children with attention-deficit/hyperactivity disorder. Atten. Deficit Hyperact. Disord. 2016;8:175–187. doi: 10.1007/s12402-016-0199-0. - DOI - PMC - PubMed
    1. Cai R.Y., Richdale A.L., Uljarević M., Dissanayake C., Samson A.C. Emotion regulation in autism spectrum disorder: Where we are and where we need to go. Autism Res. 2018;11:962–978. doi: 10.1002/aur.1968. - DOI - PubMed
    1. Shaw P., Stringaris A., Nigg J., Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Focus. 2016;14:127–144. doi: 10.1176/appi.focus.140102. - DOI - PMC - PubMed
    1. Faraone S.V., Rostain A.L., Blader J., Busch B., Childress A.C., Connor D.F., Newcorn J.H. Practitioner review: Emotional dysregulation in attention-deficit/hyperactivity disorder—Implications for clinical recognition and intervention. J. Child Psychol. Psychiatry. 2019;60:133–150. doi: 10.1111/jcpp.12899. - DOI - PubMed
    1. Joshi G., Wozniak J., Fitzgerald M., Faraone S., Fried R., Galdo M., Furtak S.L., Conroy K., Kilcullen J.R., Belser A., et al. High risk for severe emotional dysregulation in psychiatrically referred youth with autism spectrum disorder: A controlled study. J. Autism Dev. Disord. 2018;48:3101–3115. doi: 10.1007/s10803-018-3542-9. - DOI - PubMed

LinkOut - more resources